on hourly labour costs is used for productivity costs per working day/hour. RESULTS: Vacancy durations estimated in 2009 for The Netherlands, Belgium, Germany, France, the UK, Norway and Sweden range between 40-80 days. Regression analysis of the vacancy durations shows that, there is a strong negative relationship between vacancy durations and unemployment rates. When unemployment increases, vacancy durations and hence friction period decline. We also find that an increase in the vacancy rate (the ratio of the stock of vacancies to total labor force) has a positive effect on vacancy durations which can be explained by the congestion provoked by the increase in the number of vacancies competing in the labor market. CONCLUSIONS: This paper provides estimates on vacancy durations, friction periods and the price component in order to calculate the friction costs. For seven European countries, we present empirical estimates to use the friction cost method in a practical way which can improve more uniform analysis of productivity costs in economic evaluations of diseases. Our regression results confirm the validity of estimated vacancy durations which are necessary to calculate the length of friction period and friction costs.
OBJECTIVES: Productivity costs constitute a substantial proportion of the total societal costs associated with cancer. Cancer patients may leave the workforce permanently post-diagnosis, take time off during treatment and/or return to work with reduced hours or die prematurely; the associated productivity costs have rarely been considered. We applied the dominant human capital approach (HCA) and the emerging friction cost approach (FCA) to estimate breast and prostate cancer productivity costs in Ireland in 2008. METHODS: Data from a survey of breast and prostate cancer patients (nϭ358) was combined with population-level survival estimates (from the population-based National Cancer Registry) and a national wage dataset to calculate costs of temporary disability (cancer-related work absence), permanent disability (workforce departure, reduced working hours) and premature mortality, using the HCA and FCA. Sensitivity analyses were conducted for key parameters: GNP growth and discount rates for HCA and friction period and labour elasticity for FCA. RESULTS: According to the HCA, productivity costs per person amounted to €193,425 for breast and €109,154 for prostate cancer. FCA per person costs were €8103 for breast and €8205 for prostate cancer. The HCA generated higher costs for younger patients (breast cancer) due to greater lifetime earning potential. In contrast FCA resulted in higher productivity costs for older male patients (prostate) commensurate with higher earning capacity over a shorter time period. Reduced working hours post-cancer was a key driver of total HCA productivity costs. HCA costs were sensitive to assumptions about discount and growth rates. FCA costs were sensitive to assumptions about the friction period. CONCLUSIONS: This study highlights the importance of choosing the correct valuation method for chronic long-term illnesses such as cancer, being explicit about assumptions, and considering a range of cost sub-components, including those due to reduced working hours.
PC4 HEALTH SERVICES UTILIZATION, WORK ABSENTEEISM AND COSTS OF PANDEMIC INFLUENZA A (H1N1)
Garin O 1 , Galante M 1 , Sicuri E 1 , Cots F 2 , Garcia-Altés A 3 , Ferrer M 4 , Nebot M 1 , Dominguez À 1 , Alonso J 5 1 CIBERESP, Barcelona, Spain, 2 Parc de Salut Mar, Barcelona, Spain, 3 Catalan Agency for Health Information, Assessment and Quality (CAHIAQ), Barcelona, Spain, Barcelona, Barcelona, Spain, Barcelona, Spain, Spain OBJECTIVES: The aim of this study was to estimate the impact of pandemic Influenza A H1N1/2009 in terms of patient's health care services utilization, work absenteeism and associated costs. METHODS: Longitudinal, descriptive, multi-centre study of in-and outpatients with confirmed diagnosis of influenza A H1N1/2009 in Spain. Sociodemographic and clinical characteristics were gathered together with health and social resources use, at the admission or primary visit, and also after recovery. Cost analyses were conducted under a social perspective, incidence focus and with a temporal horizon of 3 months. Unit cost of resources was imputed to calculate the mean cost by inpatient and outpatient. A sensitivity analysis with variations was conducted (Monte Carlo simulation). RESULTS: A total of 172 inpatients and 224 outpatients were included, 20% and 30% of whom, respectively, were under 17 years old; 12% of inpatients were at ICU, 7.8 (SDϭ3.7) days, on average, and stayed in general wards for 9.6 (SDϭ7.7) additional days. The rest of inpatients had a mean hospitalization length of 5 (SDϭ4.4) days. The most frequently used ambulatory health resource was the primary care medical assistance; 43.8% of inpatients and 66.1% of outpatients were employed, of whom 100% (inpatients) and 91.7% (outpatients) went on sick leave. Absenteeism length was of 30 (SDϭ20.7) days for inpatients and 9 (SDϭ6.3) for outpatients. Caregivers of 21.7% of the inpatients also led work absenteeism, as well as the 8.5% of those of outpatients. The proportion of indirect cost for general-ward-inpatients was 30%. This percentage ascended to 77% in the case of outpatients. The mean costs per inpatient were €6,236 (CI95%ϭ1,384 -14,623) and €940 (CI95%ϭ66 -3,064) per outpatient. CONCLUSIONS: Hospitalizations represents the highest economic cost, together with work absenteeism. Since only a marginal proportion of influenza cases are hospitalized, productivity losses emerge as the most important impact of the disease. 
PODIUM SESSION I: IN-DEPTH STUDIES ON DIFFERENCES AND OPPORTUNITIES IN PRICING AND MARKET ACCESS

PR1 KEY MARKET ACCESS DRIVERS FOR A SUCCESSFUL HEALTH TECHNOLOGY APPRAISAL OUTCOME -THE CASE OF RHEUMATOID ARTHRITIS
OBJECTIVES:
This study evaluated several recent drug launches in Rheumatoid Arthritis (RA) to determine which factors contribute to Health Technology Appraisal (HTA) outcomes. METHODS: We reviewed the appraisals of RA drugs launched in the last five years by the following HTA agencies: England (NICE), Scotland (SMC), Sweden (TLV), France (HAS), Spain (CAHTA/CANM) and The Netherlands (CVZ). We analysed the proportion of recommended, restricted and not recommended appraisals and the reasons for these decisions. A subsequent analysis of the evidence and arguments developed in the appraisal by the HTA agency was performed. We classified them as clinical, economic, humanistic or social, in addition we analysed the outcome by country and drug. RESULTS: The listed HTA agencies issued a total of 25 appraisals (first appraisal, indication expansion and re-appraisal) for the 4 drugs analysed (certolizumab, golimumab, tocilizumab and abatacept). There were 9 recommendations for use (36%), 13 restricted use decisions (52%) and 3 decisions to not recommend for use (12%). In 96% of the cases, the study design (population, add-on vs. monotherapy, duration of trials, comparators etc.) were systematically quoted as the primary reason for the HTA agency decision. In 44% of these cases, in addition to design issues, the lack of convincing health economic data was mentioned. The reasons for favourable recommendations were 100% clinical and 56% economic, for restricted 100% clinical and 31% economic and in case of non-recommendation 67% clinical and 67% economic. CONCLUSIONS: The primary reason for restriction and non-recommendation are clinical design issues. Consequently it is recommended that manufacturers incorporate payer's expectations in their development plan early enough to influence trial design and to collect robust health economic evidence. 
PR2
VALUE-BASED PRICING IN THE UK: DEVELOPING AN EVALUATION FRAMEWORK FOR BURDEN OF ILLNESS
OBJECTIVES:
The recent UK value-based pricing (VBP) consultation proposes that burden of illness, therapeutic improvement/innovation and wider societal benefits are evaluated in addition to cost-effectiveness. This study explored attitudes among industry, academia and UK National Health Service (NHS) stakeholders to the proposed VBP framework, with a focus on how to define the burden of illness component. METHODS: Relevant literature was identified via a manual search to assess the use of VBP methodologies in other countries and potential burden of illness (BOI) criteria. In-depth, semi-structured 40-minute telephone interviews were then undertaken with 20 experts identified in UK academic centres, the pharmaceutical industry and the NHS. Discussions explored perspectives on VBP and in particular how to define and evaluate BOI. RESULTS: Proposed definitions for BOI varied significantly. Industry representatives wanted the flexibility to use a broad, variable set of criteria, while academic and NHS stakeholders wanted practical, consistent evaluation criteria with the emphasis on ensuring benefits are not 'double-counted'. Stakeholder input was used to develop a framework for assessing BOI comprising disease severity, quality of life impact, treatment availability and performance of existing treatments. Qualitative grading scales for each of the criteria were proposed. While each stakeholder group broadly endorsed VBP objectives, the research highlighted various concerns regarding its implications. In particular, the need for clear government policy and guidance, further development of acceptable evaluation methodologies (including criteria weightings), and enhanced pharmaceutical development processes to ensure evidence of sufficient quality is generated to support evaluation of product value (both at launch and over time). CONCLUSIONS: There appears to be sufficient common ground to develop a BOI assessment framework that is acceptable to both industry and NHS stakeholders. We propose a relatively simple model that could form the basis for further research and discussion, with special attention to addressing the implementation challenges. 
PR3 INDUSTRY PREPAREDNESS AGAINST GERMAN REFORMS
OBJECTIVES:
The Pharmaceutical Market Restructuring Act (AMNOG) came into action in Germany January 2011 with the aim of containing rising health care expenditure, notably by introducing mandatory benefit assessments and price negotiation for all new innovative pharmaceuticals. The impact of the reform for the pharmaceutical industry is predicted to be at its highest with repercussions beyond the country's borders, due to Germany's strategic importance in the European market. This project aimed to identify the challenges and opportunities created for the industry in terms of pricing and market access of innovative pharmaceuticals. METHODS: The impact was measured from three angles by developing hypotheses and testing them thanks to a series of exploratory interviews with pharmaceutical companies and Market access stakeholders. RESULTS: Results obtained project that the impact of the reform for the industry will be very high, increasing the importance of national stakeholders, altering the cost, time and strategy for mar-A236 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
